BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pregabalin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pregabalin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07456761-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pregabalin: Phase na readout est. (NCT07456761)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Effect of Low-dose Pregabalin Re
 tard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoper
 ative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Su
 rgery\nEstimated primary completion: November 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07456761
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05150795-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pregabalin: Phase 1 readout est. (NCT05150795)
DESCRIPTION:Pregabalin\, phase 1.\nStudy: Effect of Preoperative Oral Prega
 balin Versus Intraoperative Fentanyl on Postoperative Analgesia\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pregabalin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05150795
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630753-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Pregabalin: Phase na readout est. (NCT07630753)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Effect of Pregabalin on Optic Ne
 rve Sheath Diameter in Craniotomy Patients.\nEstimated primary completion:
  10 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pr
 egabalin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07630753
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421427-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pregabalin: Phase na readout est. (NCT07421427)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Adding Amantadine or Duloxetine 
 to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome\nEstimated pr
 imary completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pregabalin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07421427
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400471-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Pregabalin: Phase 1 readout est. (NCT07400471)
DESCRIPTION:Pregabalin\, phase 1.\nStudy: The Effects of Preemptive Multimo
 dal Analgesic on Endodontic Pain Following Root Canal Therapy.\nEstimated 
 primary completion: 30 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pregabalin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07400471
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06150898-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Pregabalin: Phase 2 readout est. (NCT06150898)
DESCRIPTION:Pregabalin\, phase 2.\nStudy: Ketorolac and Pregabalin Effects 
 on breaSt Cancer (KePreSt)\nEstimated primary completion: 20 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pregabalin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06150898
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712913-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pregabalin: Phase 3 readout est. (NCT07712913)
DESCRIPTION:Pregabalin\, phase 3\, Diabetic Peripheral Neuropathic Pain.\nS
 tudy: Extended-release Pregabalin for the Treatment of Neuropathic Pain in
  Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia\n
 Estimated primary completion: 1 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07712913
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07344467-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pregabalin: Phase na readout est. (NCT07344467)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Oral Melatonin Versus Oral Prega
 balin on Postoperative Pain and Anxiety Following Spine Surgery\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pregabalin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07344467
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913074-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pregabalin: Phase 2 readout est. (NCT07913074)
DESCRIPTION:Pregabalin\, phase 2.\nStudy: A Phase 2a Study Comparing the Ef
 ficacy\, Safety and Tolerability of Pregabalin Eye Drops Comparing With Ti
 molol Eye Drops in Adults With Glaucoma or High Eye Pressure.\nEstimated p
 rimary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pregabalin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07913074
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07171320-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pregabalin: Phase na readout est. (NCT07171320)
DESCRIPTION:Pregabalin\, phase na\, Fibromyalgia.\nStudy: The Efficacy and 
 Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromy
 algia\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07171320
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208357-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pregabalin: Phase na readout est. (NCT07208357)
DESCRIPTION:Pregabalin\, phase na\, Fibromyalgia.\nStudy: The Efficacy and 
 Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fib
 romyalgia\nEstimated primary completion: 30 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07208357
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230197-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pregabalin: Phase na readout est. (NCT07230197)
DESCRIPTION:Pregabalin\, phase na\, Fibromyalgia.\nStudy: The Efficacy and 
 Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibrom
 yalgia\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07230197
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186751-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pregabalin: Phase na readout est. (NCT07186751)
DESCRIPTION:Pregabalin\, phase na\, Fibromyalgia.\nStudy: The Efficacy and 
 Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalg
 ia\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07186751
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07880223-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pregabalin: Phase na readout est. (NCT07880223)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Comparison of Two Postoperative 
 Care Strategies After Breast Surgery\nEstimated primary completion: August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pregabalin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0788022
 3
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752134-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pregabalin: Phase 1 readout est. (NCT07752134)
DESCRIPTION:Pregabalin\, phase 1.\nStudy: Efficacy and Safety of Pregabalin
  Combined With Educational and Behavioral Intervention for Bladder Pain Sy
 ndrome/Interstitial Cystitis\nEstimated primary completion: 31 October 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pregabalin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07752134
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935252-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pregabalin: Phase na readout est. (NCT07935252)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Prolonged Multimodal Analgesia f
 or Postsurgical Pain\nEstimated primary completion: 30 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pregabalin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07935252
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614322-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Pregabalin: Phase 2 readout est. (NCT06614322)
DESCRIPTION:Pregabalin\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nS
 tudy: SPENDD: Quantitative Sensory Testing and Analgesic Response for Pain
 ful Peripheral Neuropathy.\nEstimated primary completion: 1 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pregabalin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06614322
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288528-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Pregabalin: Phase 4 readout est. (NCT07288528)
DESCRIPTION:Pregabalin\, phase 4.\nStudy: A 2x2 Factorial\, Randomized\, Op
 en-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Pa
 tients With Refractory or Unexplained Chronic Cough\nEstimated primary com
 pletion: 1 September 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pregabalin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07288528
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549490-4854@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pregabalin: Phase na readout est. (NCT07549490)
DESCRIPTION:Pregabalin\, phase na.\nStudy: Human Experimental Models of Pai
 n (HEMP)\nEstimated primary completion: 31 December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07549490
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
